Jean-Fabien Monin
Direttore Amministrativo presso AC IMMUNE SA
Patrimonio netto: 714 366 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Jean-Fabien Monin
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
32
| Public Company | Pharmaceuticals: Major | 32 |
| Public Company | Medical Specialties | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jean-Fabien Monin tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| IMMATICS N.V. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of Lausanne | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
Biotheranostics, Inc.
 Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Medical/Nursing Services | Director/Board Member Chief Executive Officer Director/Board Member | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Graduate Degree | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree Doctorate Degree | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MODERNA, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| Febit, Inc. | Director/Board Member Chairman | ||
| TRANSGENE | Biotechnology | Director/Board Member President | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
Inventages II
 Inventages II Investment ManagersFinance Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements. | Investment Managers | Founder Founder | |
| ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Swiss Institute For Intl Economics & Applied Economic Research | Chairman | ||
The Travelers Indemnity Co.
 The Travelers Indemnity Co. Specialty StoresRetail Trade Part of The Travelers Cos., Inc., The Travelers Indemnity Co. is a provider of insurance coverage for architects and engineers, as well as small businesses across various industries. The company is based in Hartford, CT. The company also offers tips for preventing damage to homes, businesses, and automobiles. The company was founded by James G. Batterson. Alan D. Schnitzer has been the CEO of the company since 2007. | Specialty Stores | Chief Operating Officer | |
| UNUM GROUP | Multi-Line Insurance | Director/Board Member | |
| HUBER+SUHNER AG | Telecommunications Equipment | Director/Board Member | |
| SWISS LIFE HOLDING AG | Life/Health Insurance | Director/Board Member | |
| Suva City Council | Corporate Officer/Principal | ||
| Richard Büchner Foundation | Director/Board Member | ||
| SCHWEIZERISCHE NATIONALBANK | Major Banks | Director/Board Member | |
| SCHINDLER HOLDING AG | Industrial Machinery | Director/Board Member | |
| Swiss Federal Commission for Economic Issues | Corporate Officer/Principal | ||
| Network for Studies on Pensions Aging Retirement | Corporate Officer/Principal | ||
| CESifo Research Network | Corporate Officer/Principal | ||
| University of St. Gallen | College/University | Corporate Officer/Principal | |
| Center for Disability & Integration | Corporate Officer/Principal | ||
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Chief Tech/Sci/R&D Officer | |
HUBER+SUHNER (UK) Ltd.
 HUBER+SUHNER (UK) Ltd. Electronic Production EquipmentElectronic Technology HUBER+SUHNER (UK) Ltd. manufactures, imports, and sells electrical and optical connectivity components and accessories. It offers radio frequency and fiber optic products including antennas, assemblies, cables, connectors and adapters, lightning and EMP protectors, and resistive components. The company was founded on March 30, 1967 and is headquartered in Bicester, the United Kingdom. | Electronic Production Equipment | Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Germania | 18 |
| Svizzera | 16 |
| Stati Uniti | 14 |
| Francia | 2 |
| Figi | 2 |
Settori
| Health Technology | 20 |
| Consumer Services | 7 |
| Finance | 7 |
| Commercial Services | 4 |
| Health Services | 3 |
Posizioni
| Director/Board Member | 161 |
| Corporate Officer/Principal | 74 |
| Chairman | 46 |
| Chief Executive Officer | 37 |
| Independent Dir/Board Member | 33 |
Contatti più connessi
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Alan Colowick | 30 |
| Monika Bütler | 25 |
| Douglas Williams | 25 |
| Stéphane Bancel | 23 |
| Mathias Hothum | 19 |
| Christian Brechot | 16 |
| Martin Velasco | 15 |
| Werner Lanthaler | 12 |
| Thomas Graney | 11 |
| Andrea Pfeifer | 11 |
| Richard Ding | 10 |
| Carl June | 9 |
| Monica Shaw | 8 |
- Borsa valori
- Insiders
- Jean-Fabien Monin
- Connessioni Società
